Aktiesnakken — November 2010
-
-
Markedet for ngal: 1,3% af patienter på intensiv. 6,1 dage/indlæggelse...1-3test/dag.
-
(for vestlig verden, usa og japan) 175mio potentielle test/år
-
hele patentsituationen med phadia, cch gennemgås. Ingen nye punkter
-
Nu over til testformater/markeder
-
manuelle metoder: 2-5% markedsandel. nok nærmest 2
-
PoC 20-25%
-
fuldauto. systemer 70-80% (homo 3/4 hetero 1/4)
-
Det er forrykt med ama..
-
starten af 2011: CE-mærket forventes
-
ngal er tilpasset til 5 maksiner
-
2 roche, 1 siemens, abott og beckton
-
fda usa forventes 2h 2011
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind